PD-1/PD-L1信号通路抑制剂在肿瘤免疫治疗中的研究进展  

Reaserch Advances of PD-1/PD-L1 Signaling Pathway Inhibitors in Immunotherapy for Treatment of Tumors

作　　者：余琪[1] 刘欣 周湘[1] 

机构地区：[1]中国药科大学,南京210009 [2]南京圣和药业股份有限公司,南京210000

出　　处：《海峡药学》2017年第5期4-8,共5页Strait Pharmaceutical Journal

摘　　要：近年来,免疫治疗成为了肿瘤治疗的新兴热点。程序性死亡因子-1(PD-1/CD279)是一种主要表达于T细胞表面上的共受体,与其配体PD-L1(B7-H1/CD274)、PD-L2(B7-DC/CD273)结合将会抑制T细胞的增殖和活化。研究表明多数肿瘤细胞都可以产生PD-L1,并且通过激活PD-1/PD-L1信号通路来抑制T细胞的免疫反应,从而达到免疫逃逸的目的,阻断该通路能增强机体内源性抗肿瘤免疫应答。目前已有多个PD-1/PD-L1信号通路抑制剂进入了临床阶段,并表现出很好的疗效和安全性。In recent years, immunotherapy has become a highlight focus in the treatment of tumor. Programmed death-1 （PD-1/CD279） is a major co-suppression receptor expressed on T cells, which will inhibit T cell proliferation and activation by binding with its ligands PD-L1 （BT-H1/CD274） ,PD-L2（ B7-DC/CD273 ）. Studies have shown that the majority of tumor ceils can produce PD-L1. It can suppress T cell immune response by activating PD-1/PD-L1 signaling pathway, which is generally believed to be the cause of tumor immune escape. Blocking the pathway can en- hance the body＇s endogenous immune response to tumors. There are several PD-1/PD-L1 signaling pathway inhibitors have entered clinical trials, and have demonstrated high efficacy and safety.

关 键 词：肿瘤治疗 PD-1/PD-L1信号通路 抑制剂 研究进展 

分 类 号：R965[医药卫生—药理学]